RESUMO
Spherical Ag particles have received considerable attention because of their unique properties as well as their applications in various fields. In the present study, the synthesis of micrometer-scale spherical Ag particles with an extremely narrow size distribution is demonstrated using a simple capacitively coupled atmospheric-pressure plasma reactor with an inkjet head. Droplets of a Ag nitrate aqueous solution are ejected from the inkjet head to synthesize Ag particles. The gaseous temperature in the reactor is adjusted such that Ag can be melted with a negligibly small vapor pressure. These particles exhibit a spherical shape with a smooth surface. The mean diameter of the particles is 0.91 ± 0.013 µm with a small coefficient of variation of 1.5%, the smallest value ever reported for Ag particles of less than 1 µm. The grain sizes of the particles are larger than 100 nm, as expected from the broadening of the X-ray diffraction peaks. The excellent monodispersity of the particles synthesized by this method may expand the applications with micrometer-scale spheres such as ball spacer, microsized ball bearing, and inks for printed electronics.
RESUMO
This study demonstrates cross-linking-filler composites in which covalent bonds between the fillers and polymer chains act as the main cross-linking points for the development of flexible and thermally conductive materials. Cross-linking-filler composites are fabricated using functionalized hexagonal boron nitride (hBN) fillers and polyrotaxane, called slide-ring polymers. The hBN particles modified with a carbon layer were produced by plasma processing in hydroquinone aqueous solution and functionalized with isocyanate groups. As the functionalized hBN provides cross-linking points for polyrotaxane, the cross-linking-filler composites can reduce cross-linking agents among polyrotaxane and exhibit considerable flexibility. Young's moduli of the cross-linking-filler composites are much lower than those of previously reported polyrotaxane composites while retaining their toughness. These values are relatively close to those of unfilled polyrotaxane elastomers, despite containing hBN fillers with a content of 50 wt %. Thus, the cross-linking-filler composites exhibit a combination of flexibility and thermal conductivity, which few hBN/elastomer composites have achieved.
RESUMO
Although hexagonal boron nitride (hBN) is a thermally conductive and electrically insulating filler in composite materials, surface modification remains difficult, which limits its dispersibility and functionalization. In this study, carbon layer formation on hBN particles by plasma processing in hydroquinone aqueous solution was investigated as a surface modification technique. Carbon components with features of polymeric hydrogenated amorphous carbon were found to be uniformly distributed on the hydroquinone-aided plasma-modified hBN (HQpBN) particles. Electron spin resonance measurements revealed abundant unpaired electrons in HQpBN, indicating that defects were formed on hBN by plasma processing and that the carbon layer contained dangling bonds. The defects on hBN could help in the attachment of the carbon layer, whereas the dangling bonds could act as reactive sites for further functionalization. The carbon layer on HQpBN was successfully functionalized with isocyanate groups, thus confirming the ability of this carbon layer to facilitate surface modification. These results demonstrate that the carbon layer formed on hBN can provide a designable interface in organic/inorganic composite materials.
RESUMO
CEL-III is a hemolytic lectin purified from the marine invertebrate Cucumaria echinata. New expression system of CEL-III was constructed, and the recombinant thioredoxin-fused CEL-III (Trx-CEL-III) showed strong hemolytic and carbohydrate-binding activity as same as authentic CEL-III. Mutation analysis of Trx-CEL-III suggested that carbohydrate binding to subdomain 1α and 2ß of CEL-III might be important for the hemolytic activity.
Assuntos
Cucumaria , Lectinas , Animais , Carboidratos , Cucumaria/metabolismo , Hemólise , Invertebrados/metabolismo , Lectinas/metabolismo , TiorredoxinasRESUMO
We present a study quantitatively demonstrating that the method of synthesis (gas phase, fixed bed, non-fixed bed) represents a determining factor in the level of crystallinity in growing single wall carbon nanotubes (SWCNTs). Using far infrared spectroscopy, the "effective length" (associated with the level of crystallinity) was estimated for CNTs grown using various synthetic methods (lab-produced and supplemented by commercially purchased SWCNTs) as a metric for crystallinity (i.e., defect density). Analysis of the observed "effective lengths" showed that the SWCNTs fell into two general groups: long and short (high and low crystallinity) synthesized by gas-phase methods and all other supported catalyst methods, respectively. Importantly, the "long" group exhibited effective lengths in the range of 700-2200 nm, which was greater than double that of the typical values representing the "short" group (110-490 nm). These results highlight the significant difference in crystallinity. We interpret that the difference in the crystallinity stemmed from stress concentration at the nanotube-catalyst interface during the growth process, which originated from various sources of mismatch in growth rates (e.g., vertically aligned array) as well as impact stress from contact with other substrates during fluidization or rotation. These results are consistent with well-accepted belief, but now are demonstrated quantitatively.
RESUMO
The importance of hydrogen in carbon nanotube (CNT) synthesis has been known as it supports the critical processes necessary for CNT growth, such as catalyst reduction. However, within the scope of our mini microplasma CNT synthesis reactor, we found that hydrogen was critical for unexpected reasons. Without hydrogen, CNT growth was inhibited and characterized by amorphous carbon particles. Optical emission spectroscopy of the microplasma revealed that without hydrogen, the high-energy electrons induced the immediate decomposition of carbon feedstock simultaneously with the catalyst feedstock, thus suppressing the formation of catalyst nanoparticles and inducing catalyst deactivation. In contrast, the inclusion of hydrogen induced less-immediate decomposition of reactant gases, through the conversion of electron energy of the plasma to thermal energy, which provided the appropriate conditions for catalyst nanoparticle formation and subsequent CNT nucleation. A simple reaction pathway model was proposed to explain these observed results and underlying mechanisms.
RESUMO
Atherosclerosis is a macrophage-related inflammatory disease that remains a leading cause of death worldwide. Magnetic iron oxide (IO) nanocrystals are clinically used as magnetic resonance imaging contrast agents and their application as a detection agent for macrophages in arterial lesions has been studied extensively. We recently fabricated heparin-modified calcium phosphate (CaP) nanoparticles loaded with a large number of IO nanocrystals via coprecipitation from a supersaturated CaP solution supplemented with heparin and ferucarbotran (IO nanocrystals coated with carboxydextran). In this study, we further increased the content of IO nanocrystals in the heparin-modified IO-CaP composite nanoparticles by increasing the ferucarbotran concentration in the supersaturated CaP solution. The increase in nanoparticle IO content caused a decrease in particle diameter without impairing its dispersibility; the nanoparticles remained dispersed in water for up to 2 h due to electrostatic repulsion between particles due to the surface modification with heparin. The nanoparticles were more effectively taken up by murine RAW264.7 macrophages compared to free ferucarbotran without showing significant cytotoxicity. A preliminaryin vivostudy showed that the nanoparticles injected intravenously into mice delivered more IO nanocrystals to macrophage-rich carotid arterial lesions than free ferucarbotran. Our nanoparticles have potential as a delivery agent of IO nanocrystals to macrophages in arterial lesions.
Assuntos
Aterosclerose/tratamento farmacológico , Fosfatos de Cálcio/administração & dosagem , Compostos Férricos/química , Estreptozocina/efeitos adversos , Administração Intravenosa , Animais , Aterosclerose/etiologia , Fosfatos de Cálcio/síntese química , Fosfatos de Cálcio/química , Fosfatos de Cálcio/farmacologia , Dextranos/química , Modelos Animais de Doenças , Nanopartículas Magnéticas de Óxido de Ferro/química , Nanopartículas de Magnetita/química , Masculino , Camundongos , Nanocompostos , Células RAW 264.7 , Resultado do TratamentoRESUMO
BACKGROUND: A 2017 meta-analysis of data from 25 randomised controlled trials (RCTs) of vitamin D supplementation for the prevention of acute respiratory infections (ARIs) revealed a protective effect of this intervention. We aimed to examine the link between vitamin D supplementation and prevention of ARIs in an updated meta-analysis. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov registry for studies listed from database inception to May 1, 2020. Double-blind RCTs of vitamin D3, vitamin D2, or 25-hydroxyvitamin D (25[OH]D) supplementation for any duration, with a placebo or low-dose vitamin D control, were eligible if they had been approved by a research ethics committee, and if ARI incidence was collected prospectively and prespecified as an efficacy outcome. Studies reporting results of long-term follow-up of primary RCTs were excluded. Aggregated study-level data, stratified by baseline 25(OH)D concentration and age, were obtained from study authors. Using the proportion of participants in each trial who had one or more ARIs, we did a random-effects meta-analysis to obtain pooled odds ratios (ORs) and 95% CIs to estimate the effect of vitamin D supplementation on the risk of having one or more ARIs (primary outcome) compared with placebo. Subgroup analyses were done to estimate whether the effects of vitamin D supplementation on the risk of ARI varied according to baseline 25(OH)D concentration (<25 nmol/L vs 25·0-49·9 nmol/L vs 50·0-74·9 nmol/L vs >75·0 nmol/L), vitamin D dose (daily equivalent of <400 international units [IU] vs 400-1000 IU vs 1001-2000 IU vs >2000 IU), dosing frequency (daily vs weekly vs once per month to once every 3 months), trial duration (≤12 months vs >12 months), age at enrolment (<1·00 years vs 1·00-15·99 years vs 16·00-64·99 years vs ≥65·00 years), and presence versus absence of airway disease (ie, asthma only, COPD only, or unrestricted). Risk of bias was assessed with the Cochrane Collaboration Risk of Bias Tool. The study was registered with PROSPERO, CRD42020190633. FINDINGS: We identified 1528 articles, of which 46 RCTs (75 541 participants) were eligible. Data for the primary outcome were obtained for 48 488 (98·1%) of 49 419 participants (aged 0-95 years) in 43 studies. A significantly lower proportion of participants in the vitamin D supplementation group had one or more ARIs (14 332 [61·3%] of 23 364 participants) than in the placebo group (14 217 [62·3%] of 22 802 participants), with an OR of 0·92 (95% CI 0·86-0·99; 37 studies; I2=35·6%, pheterogeneity=0·018). No significant effect of vitamin D supplementation on the risk of having one or more ARIs was observed for any of the subgroups defined by baseline 25(OH)D concentration. However, protective effects of supplementation were observed in trials in which vitamin D was given in a daily dosing regimen (OR 0·78 [95% CI 0·65-0·94]; 19 studies; I2=53·5%, pheterogeneity=0·003), at daily dose equivalents of 400-1000 IU (0·70 [0·55-0·89]; ten studies; I2=31·2%, pheterogeneity=0·16), for a duration of 12 months or less (0·82 [0·72-0·93]; 29 studies; I2=38·1%, pheterogeneity=0·021), and to participants aged 1·00-15·99 years at enrolment (0·71 [0·57-0·90]; 15 studies; I2=46·0%, pheterogeneity=0·027). No significant interaction between allocation to the vitamin D supplementation group versus the placebo group and dose, dose frequency, study duration, or age was observed. In addition, no significant difference in the proportion of participants who had at least one serious adverse event in the vitamin supplementation group compared with the placebo group was observed (0·97 [0·86-1·07]; 36 studies; I2=0·0%, pheterogeneity=0·99). Risk of bias within individual studies was assessed as being low for all but three trials. INTERPRETATION: Despite evidence of significant heterogeneity across trials, vitamin D supplementation was safe and overall reduced the risk of ARI compared with placebo, although the risk reduction was small. Protection was associated with administration of daily doses of 400-1000 IU for up to 12 months, and age at enrolment of 1·00-15·99 years. The relevance of these findings to COVID-19 is not known and requires further investigation. FUNDING: None.
Assuntos
Infecções Respiratórias/dietoterapia , Infecções Respiratórias/prevenção & controle , Vitamina D/administração & dosagem , Suplementos Nutricionais , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do TratamentoRESUMO
BACKGROUND: A 2017 meta-analysis of data from 25 randomised controlled trials of vitamin D supplementation for the prevention of acute respiratory infections revealed a protective effect of the intervention. Since then, 20 new RCTs have been completed. METHODS: Systematic review and meta-analysis of data from randomised controlled trials (RCTs) of vitamin D for ARI prevention using a random effects model. Pre-specified sub-group analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration or dosing regimen. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry from inception to 1st May 2020. Double-blind RCTs of supplementation with vitamin D or calcidiol, of any duration, were eligible if they were approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration, were obtained from study authors. The study was registered with PROSPERO (no. CRD42020190633). FINDINGS: We identified 45 eligible RCTs (total 73,384 participants). Data were obtained for 46,331 (98.0%) of 47,262 participants in 42 studies, aged 0 to 95 years. For the primary comparison of vitamin D supplementation vs. placebo, the intervention reduced risk of ARI overall (Odds Ratio [OR] 0.91, 95% CI 0.84 to 0.99; P for heterogeneity 0.01). No statistically significant effect of vitamin D was seen for any of the sub-groups defined by baseline 25(OH)D concentration. However, protective effects were seen for trials in which vitamin D was given using a daily dosing regimen (OR 0.75, 95% CI 0.61 to 0.93); at daily dose equivalents of 400-1000 IU (OR 0.70, 95% CI 0.55 to 0.89); and for a duration of ≤12 months (OR 0.82, 95% CI 0.72 to 0.93). No significant interaction was seen between allocation to vitamin D vs. placebo and dose frequency, dose size, or study duration. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0.97, 95% CI 0.86 to 1.09). Risk of bias within individual studies was assessed as being low for all but three trials. A funnel plot showed left-sided asymmetry (P=0.008, Egger's test). INTERPRETATION: Vitamin D supplementation was safe and reduced risk of ARI, despite evidence of significant heterogeneity across trials. Protection was associated with administration of daily doses of 400-1000 IU vitamin D for up to 12 months. The relevance of these findings to COVID-19 is not known and requires investigation. FUNDING: None.
RESUMO
To evaluate the effects of 25-hydroxyvitamin D3 (25OHD) on symptoms at the onset of the upper respiratory tract infection (URTI) in subjects with insufficient or deficient serum 25-hydroxyvitamin D levels, we conducted a post hoc analysis of data from a randomized, placebo-controlled study; the subjects received 10 µg of 25OHD per day or a placebo for 16 weeks. The Wisconsin Upper Respiratory Symptom Survey-21 was used to determine URTI. The study endpoints included WURSS-21 scores, number of URTI events, and proportion of medication (antibiotics, antipyretic analgesics) usage. We found that the physical symptom scores for "Runny nose," "Sneezing," and "Head congestion" were significantly lower in the 25OHD group than in the placebo group; for all items except "Breathe easily, "the quality of life" scores were significantly improved in the 25OHD group. There was no significant difference in the number of URTI events or the proportion of medication use between the groups. Collectively, the findings of this study indicate that a sufficient 25OHD intake can reduce physical symptoms at the onset of upper respiratory tract infection, particularly nasal symptoms, and may improve the quality of life at the time of onset.
Assuntos
Calcifediol/uso terapêutico , Infecções Respiratórias/tratamento farmacológico , Analgésicos não Narcóticos , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Qualidade de Vida , Sistema Respiratório , Inquéritos e Questionários , Vitamina D/análogos & derivados , WisconsinRESUMO
The development of stretchable elastomer composites with considerable mechanical strength and electrical conductivity is desired for future applications in communication tools, healthcare, and robotics. Herein, we have developed a novel stretchable elastomer composite by employing a slide-ring (SR) material as a matrix for restoration and graphene oxide (GO) as a precursor for a conductive filler. Highly dispersed GO in an organic solvent, prepared via a new method developed by the authors, allowed the uniform dispersion of GO into the matrix by simply mixing the solvent and SR. The resultant SR/GO composite exhibited considerably high mechanical toughness and cyclic durability. These properties were approximately maintained after pulse laser irradiation to add electrical conductivity on the composite by photoreducing of the dispersed GO, and its electrical conductivity was higher than that of the SR/graphene, carbon nanotubes, or graphite composites. The potential of the SR/GO composite as a stretchable base substrate for wearable devices was demonstrated by producing a prototype humidity sensor, a human motion monitoring sensor, and an electrical heater based on the composite with conductive circuits drawn using pulse laser patterning.
RESUMO
A 69-year-old man was admitted because of subacute development of lower limb weakness from one month ago. He showed central obesity, gynecomastia, dorsal fat pad ("buffalo hump"), and proximal muscle weakness in the lower extremities (manual muscle test 4). Needle EMG, muscle MRI and labolatry screening including CPK were negative for neuromuscular diseases, except for the hypogenitalism accidentally detected in MRI. Although blood corticol was in normal range, the levels of serum ACTH and 24-hour urinary free cortisol excretion were high, and the dexamethasone suppression tests were positive. Brain MRI showed a small pituitary mass with gadolinium enhancement, and ACTH measurement from petrosal sinus sampling after CRH stimulation lead to the diagnosis of definite Cushing disease. Moreover, he also showed low testosterone and elevated LH and FSH. Chromosome banding revealed 47 XXY in 22 in 30 cells, leading to the diagnosis of mosaic Klinefelter syndrome. The supplementation with testosterone was partially effective for his weakness. The surgical resection of pituitary microadenoma resulted in the full recovery. Either Klinefelter syndrome or mild Cushing disease alone was insufficient as a cause of the muscle weakness in this patient. It is plausible that the mild elevation of cortisol accompanied by the lack of tesstelone may underlie the weakness, probably linked to impaired balance between muscle anabolism and catabolism.
Assuntos
Síndrome de Klinefelter/complicações , Síndrome de Klinefelter/diagnóstico , Doenças Musculares/etiologia , Hipersecreção Hipofisária de ACTH/complicações , Hipersecreção Hipofisária de ACTH/diagnóstico , Doença Aguda , Adenoma/complicações , Adenoma/cirurgia , Hormônio Adrenocorticotrópico/sangue , Idoso , Biomarcadores/sangue , Biomarcadores/urina , Bandeamento Cromossômico , Hormônio Foliculoestimulante/sangue , Humanos , Hidrocortisona/urina , Hormônio Luteinizante/sangue , Imageamento por Ressonância Magnética , Masculino , Debilidade Muscular/etiologia , Doenças Musculares/diagnóstico , Doenças Musculares/terapia , Neoplasias Hipofisárias/complicações , Neoplasias Hipofisárias/cirurgia , Testosterona/administração & dosagem , Testosterona/deficiência , Resultado do TratamentoRESUMO
A 48-year-old woman with a 3-month history of spontaneously resolving stiff leg symptom at the age of 43 years presented with progressive onset of leg rigidity, walking difficulty, and myoclonic jerks. On admission she had marked stiffness in her foot joints with symmetric sustained dorsiflexion of the ankles and toes, with spontaneous and reflex myoclonic jerks easily provoked by knee tendon tap. She appeared to have a spastic gait due to stiffness in her legs. Needle electromyogram (EMG) examination revealed continuous motor unit activity in the tibialis anterior muscle at rest even when voluntary contraction of the gastrocnemius muscle was instructed, but no myokimic discharge or acute denervation sign was seen. The laboratory tests were unremarkable, including glutamic acid decarboxylase antibody. Cerebrospinal fluid (CSF) examination was also normal, without oligoclonal bands or elevated IgG index. She was diagnosed with stiff-limb syndrome based on neurologic examination and needle EMG findings, and she was treated with intravenous high-dose methylprednisolone (500â mg/day, 3 days), resulting in marked improvement in her symptoms. Anti-glycine receptor antibodies were subsequently identified in her archived serum and CSF obtained before immunotherapy. She was then started on oral prednisolone (30â mg/day) and had been free of symptoms.
Assuntos
Autoanticorpos/sangue , Autoanticorpos/líquido cefalorraquidiano , Receptores de Glicina/imunologia , Rigidez Muscular Espasmódica/diagnóstico , Rigidez Muscular Espasmódica/tratamento farmacológico , Administração Oral , Biomarcadores/sangue , Biomarcadores/líquido cefalorraquidiano , Eletromiografia , Feminino , Glucocorticoides/administração & dosagem , Humanos , Metilprednisolona/administração & dosagem , Pessoa de Meia-Idade , Prednisolona/administração & dosagem , Pulsoterapia , Rigidez Muscular Espasmódica/imunologia , Resultado do TratamentoRESUMO
Calcium phosphate (CaP) coating is an effective method for surface-functionalization of bioinert materials and for production of osteoconductive implants. Recently, we developed a laser-assisted biomimetic process (LAB process) for facile and area-specific CaP coating. In this study, the LAB process was applied to chemically stable and mechanically durable poly(etheretherketone) (PEEK), which has become widely used as an orthopedic and dental implant material. The LAB process was carried out by irradiating pulsed Nd:YAG laser light (355 nm) onto a PEEK substrate that was immersed in supersaturated CaP solution. The CaP coating applicability depended on laser fluence, i.e., CaP successfully formed on PEEK surface after the LAB process at 2 W/cm2. Further increase in laser fluence did not result in the successful formation. At the optimal fluence of 2 W/cm2, the laser-irradiated PEEK surface was modified and heated to induce heterogeneous CaP precipitation within 10 min in CaP solution, followed by further CaP growth over the irradiation time (tested up to 30 min). The LAB process improved the cytocompatibility of PEEK surface with osteoblastic MC3T3-E1 cells. Furthermore, the LAB-processed CaP-coated PEEK substrate formed a dense hydroxyapatite layer on its surface in the simulated body fluid, suggesting the osteoconductivity of this material. The present LAB process can be a useful new tool to produce osteoconductive PEEK-based implants.
Assuntos
Fosfatos de Cálcio , Materiais Revestidos Biocompatíveis/química , Cetonas/química , Polietilenoglicóis/química , Próteses e Implantes , Benzofenonas , Lasers , Polímeros , Propriedades de SuperfícieRESUMO
We present NiO/Ni composite particles with face-centered cubic (fcc) structure prepared by a pulsed laser irradiation of NiO nanoparticles dispersed in liquid. The sizes of particles and the Ni content in NiO/Ni composites were controlled by tuning the laser parameters, such as laser fluence and irradiation time. We found that the weight fraction of Ni has a significant impact on magnetic properties of composite particles. Large exchange bias (HEB) and coercivity field (HC) were observed at 5 K due to the creation of heterojunctions at interfaces of ferromagnetic Ni and antiferromagnetic NiO. For the NiO/Ni composites with 80% of NiO we have observed the largest values of exchange bias (175 Oe) and coercive field (950 Oe), but the increase of Ni weight fraction resulted in the decrease of both HC and HEB values.
RESUMO
We developed a facile one-pot fabrication process for magnetic iron oxide-calcium phosphate (IO-CaP) composite nanoparticles via coprecipitation in labile supersaturated CaP solutions containing IO nanocrystals. All the source solutions used were clinically approved for injection, including water and magnetic IO nanocrystals (ferucarbotran, used as a negative magnetic resonance imaging (MRI) contrast agent). This ensured that the resulting nanoparticles were pathogen- and endotoxin-free. The dispersants used were clinically approved heparin sodium (heparin) or adenosine triphosphate disodium hydrate (ATP), which were added to the IO-containing labile supersaturated CaP solutions. Both heparin and ATP coprecipitated with CaP and ferucarbotran to form heparin- and ATP-modified IO-CaP nanoparticles, respectively, with a hydrodynamic diameter of a few hundred nanometers. Both the resulting nanoparticles exhibited relatively large negative zeta potentials, caused by the negatively charged functional groups in heparin and ATP, which improved the particle dispersibility when compared to non-modified IO-CaP nanoparticles. The heparin-modified IO-CaP nanoparticles were effectively ingested by murine macrophages (RAW264.7) without showing significant cytotoxicity but barely ingested by non-phagocytotic human umbilical vein endothelial cells, indicating the potential of these nanoparticles for targeted delivery to macrophages. The heparin-modified IO-CaP nanoparticles exhibited a negative contrast enhancing ability for MRI. Our results show that IO-CaP nanoparticles have potential as delivery and MRI contrast agents for macrophages.
Assuntos
Meios de Contraste/química , Portadores de Fármacos , Imageamento por Ressonância Magnética/métodos , Nanocompostos/química , Nanopartículas/metabolismo , Trifosfato de Adenosina/química , Animais , Transporte Biológico , Fosfatos de Cálcio/química , Dextranos/química , Compostos Férricos/química , Heparina/química , Células Endoteliais da Veia Umbilical Humana , Humanos , Nanopartículas de Magnetita/química , Camundongos , Nanocompostos/ultraestrutura , Nanopartículas/química , Nanopartículas/ultraestrutura , Células RAW 264.7 , Especificidade da Espécie , Eletricidade EstáticaRESUMO
We successfully produced water-dispersible reduced graphene oxide (rGO) by pH tuning liquid-phase photoreduction. In this method, the stabilizers and chemical modification usually used for dispersing rGO are not required. The stable carboxyl groups continue to ionize throughout the photoreduction process under alkaline conditions and continue to provide water-dispersible rGO. Moreover, the decomposition of GO into CO2 is prevented, and the production of defects is largely avoided. This is because the epoxide groups on the GO nanosheets that lead to decomposition are converted into hydroxide groups under alkaline conditions. Thus, this simple aggregation-, defect-, and stabilizer-free method is potentially important for the future application of rGO.
RESUMO
The electrical transport and thermoelectric property of boron carbide nanowires synthesized by a carbothermal method are reported. It is demonstrated that the nanowires achieve a higher Seebeck coefficient and power factor than those of the bulk samples. The conduction mechanism of the nanowires at low temperatures below 300 K is different from that of the sintered-polycrystalline and single-crystal bulk samples. In a temperature range of 200-450 K, there is a crossover between electrical conduction by variable-range hopping and phonon-assisted hopping. The inhomogeneous carbon concentration and planar defects, such as twins and stacking faults, in the nanowires are thought to modify the bonding nature and electronic structure of the boron carbide crystal substantially, causing differences in the electrical conductivity and Seebeck coefficient. The effect of boundary scattering of phonon at nanostructured surface on the thermal conductivity reduction is discussed.
RESUMO
We achieved rapid, surfactant-free, and one-pot fabrication of antibacterial calcium phosphate (CaP) submicrospheres containing silver nanoparticles by combining physical laser and chemical coprecipitation processes. In this physicochemical process, weak pulsed laser irradiation (20min) was performed on a labile CaP reaction mixture supplemented with silver ions as a light-absorbing agent. The silver content in the submicrospheres was controlled for a wide range (Ag/P elemental ratio varied from 0.60 to 62.0) by tuning the initial concentration of silver ions (from 5 to 20mM) in the CaP reaction mixture. At the silver concentration of 5mM, we obtained unique nanocomposite particles: CaP submicrospheres (average diameter of approximately 500nm) containing metallic silver nanoparticles dispersed throughout, as a result of CaP and silver coprecipitation with simultaneous photoreduction of silver ions and spheroidization of the coprecipitates. These CaP submicrospheres containing silver nanoparticles (ca. 0.3mg silver per 1mg submicrospheres) exhibited antibacterial activity against major pathogenic oral bacteria, i.e., Streptococcus mutans, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis. Moreover, the CaP submicrospheres dissolved and neutralized the acidic environment generated by Streptococcus mutans, demonstrating their potential as acid-neutralizing and remineralizing agents. The present process and resulting antibacterial CaP-based submicrospheres are expected to be useful in dental healthcare and infection control. STATEMENT OF SIGNIFICANCE: Nano- and microsized spheres of calcium phosphate (CaP) containing silver nanoparticles have great potential in dental applications. Conventional fabrication processes were time-consuming or weak regarding the size/shape control of the spheres. In this study, we achieved a simple (one-pot), rapid (20-min irradiation), and surfactant-free fabrication of CaP submicrospheres containing silver nanoparticles by pulsed laser irradiation to a mixture of calcium, phosphate, and silver ion solutions. The resulting CaP submicrospheres contained metallic silver nanoparticles dispersed throughout in a sequence of reactions: CaP and silver coprecipitation, laser-induced melting and spheroidization of the coprecipitates, and photoreduction of silver ions. These submicrospheres showed antibacterial activity against oral bacteria and acid-neutralizing property in the bacterial suspension, and hence are worth considering for dental applications.
Assuntos
Antibacterianos/farmacologia , Fosfatos de Cálcio/farmacologia , Lasers , Nanopartículas Metálicas/química , Microesferas , Prata/farmacologia , Precipitação Química , Concentração de Íons de Hidrogênio , Nanopartículas Metálicas/ultraestrutura , Testes de Sensibilidade Microbiana , Nefelometria e Turbidimetria , Oxirredução , Streptococcus mutans/efeitos dos fármacos , Streptococcus mutans/ultraestruturaRESUMO
Surface-mediated gene delivery systems have many potential applications in tissue engineering. We recently fabricated an assembly consisting of DNA-amorphous calcium phosphate (DNA-ACP) nanocomposite spheres on a polymer substrate via coprecipitation in a labile supersaturated calcium phosphate (CaP) solution and demonstrated the assembly's high gene delivery efficacy. In this study, we conducted a detailed investigation of the coprecipitation process in solution and revealed that the negatively charged DNA molecules were immobilized in the ACP spheres during the initial stage of coprecipitation and functioned as both sphere-dispersing and size-regulating agents. As a result, the DNA-ACP nanocomposites grew into size-regulated submicrospheres in solution and assembled onto the substrate via gravity sedimentation. The assembled nanocomposite spheres were chemically anchored to the substrate surface through an intermediate layer of CaP-based nanoparticles that was formed heterogeneously at the substrate surface. The coprecipitation conditions, i.e., coprecipitation time and Ca and P concentrations in solution, greatly affected the state of assembly of the nanocomposite spheres, thereby influencing the gene expression level of the cells cultured on the substrate. Increasing the number density and decreasing the size of the nanocomposite spheres did not always increase the assembly's gene delivery efficacy (per surface area of the substrate) due to adverse effects on cellular viability. As demonstrated herein, controlling the coprecipitation conditions is important for designing a cell-stimulating and biocompatible scaffold surface consisting of an assembly of DNA-ACP nanocomposite spheres.